SomaScan® Platform confirmation and performance validation


The SomaScan® Platform for proteomic profiling uses 7,288 (7K) SOMAmer® reagents, single-stranded DNA aptamers, to 6,596 unique human protein targets. The modified aptamer binding reagents1, SomaScan Assay2, its performance characteristic for 5K3 and 7K4 content sets, and specificity5,6,7 to human targets have been previously described. We combine profiles of validation and performance metrics with orthogonal confirmation of specificity from published literature to provide a comprehensive view of the specificity and utility of the SomaScan Platform.


Validation of SOMAmer reagents results in a set of metrics that profile performance of the reagents to the protein standards used
for discovery. These include linear ranges and affinity measures: dose response 50 (apparent K D ), and solution K D . Validation of the SomaScan Platform includes replicates of individual and pooled samples over 15 assay runs in both plasma and serum.

Population ranges and performance are generated from matched plasma and serum drawn from more than 1,000 U.S. normal volunteers. Reproducibility and signaling metrics are summarized and reported. Production use of the SomaScan Platform includes replicates to monitor the accuracy and precision of the assay over time. Results from more than 3,000 replicates are aggregated and reported.

Secondary confirmation of specificity is explored using published outcomes from alternative proteomic or genomic profiling methods. Results are extracted from the literature and assembled by reagent identifier. Alternative experiments that confirm protein targets are described and reported separately.


The SomaScan® Platform for proteomic profiling relies on a deep validation workflow for reagents and for the platform. Transparency in the methods and results is critical to help users interpret platform results.


Ted Johnson
Darryl Perry

SomaLogic Operating Co., Inc., Boulder, CO USA


  1. Rohloff JC, Gelinas AD, Jarvis TC, et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Molecular Therapy Nucleic Acids 2014; 3: e201.
  2. Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoSOne 2010; 5(12): e15004.
  3. Kim CH, Tworoger SS, Stampfer MJ, et al. Stability and reproducibility of proteomic profiles measured with an aptamer based platform. Sci Rep 2018; 8(1): 8382.
  4. Candia J, Daya GN, Tanaka T, et al. Assessment of variability in the plasma 7K SomaScan proteomics assay. Sci Rep 12, 17147 (2022).
  5. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature 2018; 558(7708): 73-9.
  6. Emilsson V, Ilkov M, Lamb JR, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 2018; 361(6404): 769-73.
  7. Pietzner M, et al. Mapping the proteo-genomic convergence of human diseases. Science 2021; Vol 374, Issue 6569
  8. Candia J, et al. Assessment of variability in the plasma 7K SomaScan proteomics assay. Sci Rep 2022, Oct 13;12(1):17147. doi: 10.1038/s41598-022-22116-0. PMID: 36229504; PMCID: PMC9561184.

Learn more by downloading this poster

Download poster

Share with colleagues

More posters

PosterQuantitative immunology protein panel built on the SomaScan Assay platform

The SomaScan® assay is a highly multiplexed proteomic assay that uses SOMAmer® reagents to detect proteins in various biological samples. The latest version of the SomaScan assay allows researchers to measure over 11,000 proteins in human blood. The SomaScan assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer reagent abundance quantified using DNA microarrays.

Learn more

PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points

The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.

Learn more

PosterStatin signature: using proteomics to detect pharmacological fingerprints

Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).

Learn more

Explore posters in our interactive viewer